Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Gefitinib in Metastatic Neuroendocrine Tumors
NCT00075439Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2003
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in Neuroendocrine Neoplasm (NEN), sponsored by National Cancer Institute. Primary endpoint: Proportion of patients progression-free at 6 months. Started Dec 2003; status: completed.
02
Drugs
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00075439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075439.